We were intrigued by the profound effects that CD4+ T cells had on CD8+ T cell-dependent protective immunity against MCA sarcomas that do not express MHC-II proteins, and therefore decided to study the interdependency between MHC-I and MHC-II neoAg responses in promoting antitumour efficacy. Here, CD8A is linked to sarcoma.